MedTrace Logo

Sample Collection Study for the CellMax Life Circulating Tumor Cell and Circulating Tumor DNA Platforms for the Early Detection of Colorectal Cancer and Adenomas

NCT05127096 · Status: UNKNOWN · Type: OBSERVATIONAL · Enrollment: 1000

Last updated 2021-11-19

No results posted yet for this study

Summary

The purpose of this study is to collect clinical specimens from subjects with a diagnosis of colorectal cancer/advanced adenoma or undergoing a screening colonoscopy and meeting study eligibility criteria.

Conditions

  • Colorectal Cancer Screening

Interventions

DIAGNOSTIC_TEST

FirstSight blood test

FirstSight blood test for colorectal cancer screening

Sponsors & Collaborators

  • CellMax Life

    lead INDUSTRY

Principal Investigators

  • Rui Mei, PhD · CellMax Life

Eligibility

Min Age
45 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2020-12-15
Primary Completion
2022-09-30
Completion
2022-12-30
FDA Device
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05127096 on ClinicalTrials.gov